Skip to main content

Table 2 Kaplan-Meier progression-free survival (PFS) and overall survival estimates stratified by CTC level and patient and tumor characteristics in patients with newly diagnosed stage III inflammatory breast cancer

From: Circulating tumor cells in newly diagnosed inflammatory breast cancer

  Progression-free survival Overall survival
Variable Hazard ratio Lower 95% CI Upper 95% CI P value Hazard ratio Lower 95% CI Upper 95% CI P value
All patients         
<1 CTC versus ≥1 CTC 0.66 0.31 1.39 0.29 0.57 0.25 1.31 0.21
<5 CTC versus ≥5 CTC 0.69 0.26 1.78 0.39 0.72 0.26 2.00 0.48
ER/PR positive for either         
<1 CTC versus ≥1 CTC 0.59 0.23 1.53 0.28 0.59 0.18 1.94 0.40
<5 CTC versus ≥5 CTC 0.33 0.06 1.70 0.04 0.33 0.05 2.18 0.08
ER/PR negative for both         
<1 CTC versus ≥1 CTC 0.76 0.22 2.69 0.69 1.14 0.55 2.39 0.70
<5 CTC versus ≥5 CTC 1.14 0.31 4.14 0.85 1.05 0.28 3.91 0.94
HER-2/neu positive         
<1 CTC versus ≥1 CTC 0.64 0.15 2.77 0.58 0.37 0.07 1.97 0.34
<5 CTC versus ≥5 CTC 1.25 0.27 5.71 0.79 0.97 0.18 5.33 0.97
HER-2/neu negative         
<1 CTC versus ≥1 CTC 0.62 0.26 1.49 0.29 0.51 0.19 1.37 0.18
<5 CTC versus ≥5 CTC 0.42 0.11 1.59 0.08 0.51 0.13 2.05 0.23
Triple negative         
<1 CTC versus ≥1 CTC 0.40 0.11 1.51 0.24 0.31 0.08 1.14 0.11
<5 CTC versus ≥5 CTC 0.56 0.11 2.71 0.39 0.60 0.13 2.82 0.45
High grade         
<1 CTC versus ≥1 CTC 0.65 0.28 1.47 0.31 0.42 0.17 1.06 0.09
<5 CTC versus ≥5 CTC 0.56 0.19 1.69 0.22 0.44 0.13 1.46 0.09
Low/intermediate grade         
<1 CTC versus ≥1 CTC 0.87 0.15 5.08 0.87 1.34 0.18 9.70 0.76
<5 CTC versus ≥5 CTC 1.44 0.20 10.50 0.74 NAa NAa NAa 0.19
  1. ER, estrogen receptor; NR, not reached; PR, progesterone receptor; NA, not applicable.
  2. aNo events in patients with five or more CTCs.